Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Enanta Pharmaceuticals In...

    NASDAQ: ENTA · Real-Time Price · USD
    7.08
    -0.20 (-2.75%)
    At close: Jun 17, 2025, 3:59 PM
    7.05
    -0.49%
    After-hours: Jun 17, 2025, 04:04 PM EDT

    Enanta Pharmaceuticals Statistics

    Share Statistics

    Enanta Pharmaceuticals has 21.38M shares outstanding. The number of shares has increased by 0.72% in one year.

    Shares Outstanding

    n/a
    		 21.38M

    Shares Change (YoY)

    n/a
    		 0.72%

    Shares Change (QoQ)

    n/a
    		 0.65%

    Owned by Institutions (%)

    n/a
    		 90.82%

    Shares Floating

    n/a
    		 19.86M

    Failed to Deliver (FTD) Shares

    n/a
    		 104

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 2.72M, so 12.73% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.72M

    Short % of Shares Out

    n/a
    		 12.73%

    Short % of Float

    n/a
    		 13.53%

    Short Ratio (days to cover)

    n/a
    		 25.92

    Valuation Ratios

    The PE ratio is -1.89 and the forward PE ratio is -2.36. Enanta Pharmaceuticals's PEG ratio is 0.13.

    PE Ratio

    n/a
    		 -1.89

    Forward PE

    n/a
    		 -2.36

    PS Ratio

    n/a
    		 3.24

    Forward PS

    n/a
    		 4.3

    PB Ratio

    n/a
    		 1.7

    P/FCF Ratio

    n/a
    		 -2.27

    PEG Ratio

    n/a
    		 0.13
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Enanta Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.21, with a Debt / Equity ratio of 0.43.

    Current Ratio

    n/a
    		 5.21

    Quick Ratio

    n/a
    		 5.21

    Debt / Equity

    n/a
    		 0.43

    Debt / EBITDA

    n/a
    		 -0.53

    Debt / FCF

    n/a
    		 -0.57

    Interest Coverage

    n/a
    		 -11.12

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $516,297.71

    Profits Per Employee

    n/a
    		 $-885,839.69

    Employee Count

    n/a
    		 131

    Asset Turnover

    n/a
    		 0.18

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -1.74M

    Effective Tax Rate

    n/a
    		 1.48%

    Stock Price Statistics

    The stock price has increased by -39.85% in the last 52 weeks. The beta is 0.77, so Enanta Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.77

    52-Week Price Change

    n/a
    		 -39.85%

    50-Day Moving Average

    n/a
    		 5.83

    200-Day Moving Average

    n/a
    		 7.8

    Relative Strength Index (RSI)

    n/a
    		 61.28

    Average Volume (20 Days)

    n/a
    		 198,938

    Income Statement

    In the last 12 months, Enanta Pharmaceuticals had revenue of 67.64M and earned -116.05M in profits. Earnings per share was -5.48.

    Revenue

    n/a
    		 67.64M

    Gross Profit

    n/a
    		 67.64M

    Operating Income

    n/a
    		 -121.69M

    Net Income

    n/a
    		 -116.05M

    EBITDA

    n/a
    		 -104.51M

    EBIT

    n/a
    		 -106.85M

    Earnings Per Share (EPS)

    n/a
    		 -5.48
    Full Income Statement

    Balance Sheet

    The company has 37.23M in cash and 55.47M in debt, giving a net cash position of -18.23M.

    Cash & Cash Equivalents

    n/a
    		 37.23M

    Total Debt

    n/a
    		 55.47M

    Net Cash

    n/a
    		 -18.23M

    Retained Earnings

    n/a
    		 -323.04M

    Total Assets

    n/a
    		 322.99M

    Working Capital

    n/a
    		 196.91M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -78.76M and capital expenditures -17.95M, giving a free cash flow of -96.71M.

    Operating Cash Flow

    n/a
    		 -78.76M

    Capital Expenditures

    n/a
    		 -17.95M

    Free Cash Flow

    n/a
    		 -96.71M

    FCF Per Share

    n/a
    		 -4.57
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -179.92% and -171.58%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -179.92%

    Pretax Margin

    n/a
    		 -174.15%

    Profit Margin

    n/a
    		 -171.58%

    EBITDA Margin

    n/a
    		 -154.52%

    EBIT Margin

    n/a
    		 -179.92%

    FCF Margin

    n/a
    		 -142.99%

    Dividends & Yields

    ENTA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ENTA is $19, which is 161.7% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $19

    Price Target Difference

    n/a
    		 161.7%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -1.26

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist